Role of PTK-7 in Acute Myeloid Leukemias
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Other: Bone marrow aspirationOther: Blood sampling
- Registration Number
- NCT02860793
- Lead Sponsor
- Institut Paoli-Calmettes
- Brief Summary
The pseudo tyrosine kinase receptor 7 (PTK7) is an orphan tyrosine kinase receptor assigned to the planar cell polarity pathway. PTK7 is expressed in normal myeloid progenitors and CD34(+) CD38(-) bone marrow cells in humans. It is also expressed in acute myeloid leukemia (AML) and is mostly assigned to granulocytic lineage differentiation. In AML, PTK7 seems to convey promigratory and antiapoptotic signals into the cell and represents an independent prognosis factor of survival in patients treated with induction chemotherapy. This study aims at:
* evaluating the impact of PTK7 expression on primary AML cells ex vivo
* evaluating the diagnostic and prognostic value of a soluble form of PTK7
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 10
- Age> 18 years
- AML at diagnosis, not previously treated
- Treatment by induction chemotherapy
- Signed informed consent
- Affiliation to the French social security system
- pregnant woman(or of childbearing potential) or breastfeeding woman
- emergency
- patients deprived of liberty or placed under the authority of a tutor
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description AML patients at diagnosis Bone marrow aspiration - AML patients at diagnosis Blood sampling -
- Primary Outcome Measures
Name Time Method Soluble PTK7 measurement in the serum 12 years Evaluation PTK7+ and PTK7- AML cells hematopoietic homing abilities in xenografted mice by in vivo bioluminescence imaging 1 day
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Institut Paoli Calmettes
🇫🇷Marseille, Bouches du Rhone, France